DarunavirThird Party Manufacturing in India

Darunavir is a second-generation, non-peptidic HIV-1 protease inhibitor that prevents the maturation of infectious virions by blocking the proteolytic cleavage of viral polyproteins. HIV-1 protease is a homodimeric aspartyl protease essential for processing the Gag and Gag-Pol polyprotein precursors into functional structural proteins and enzymes — namely the matrix, capsid, nucleocapsid, reverse transcriptase, integrase, and protease itself. Darunavir binds with exceptionally high affinity to the active site of HIV-1 protease, forming extensive hydrogen bond interactions with the backbone atoms of the enzyme, particularly at the Asp25-Asp25' catalytic dyad and the flap region. The dissociation constant of the darunavir-protease complex is approximately 4.5 x 10⁻¹² M, which is 100 to 1000 times lower than that of first-generation protease inhibitors, reflecting the extraordinary binding strength of this molecule. Darunavir was specifically designed to fit tightly within the substrate envelope of HIV-1 protease, meaning it occupies the same three-dimensional space as the natural peptide substrate. This design strategy makes darunavir effective against viral strains that have developed resistance to earlier protease inhibitors, because resistance mutations tend to occur in regions of the enzyme where the substrate envelope constraint is less critical for darunavir binding. The drug also inhibits the dimerisation of HIV-1 protease subunits, further suppressing proteolytic activity. Darunavir is always co-administered with low-dose ritonavir as a pharmacokinetic booster that inhibits CYP3A4-mediated metabolism, thereby increasing darunavir plasma levels and extending its half-life.

Therapeutic Uses

Darunavir, in combination with low-dose ritonavir and other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients three years of age and older.

• Treatment-Naive Adults: Darunavir 800mg with ritonavir 100mg once daily, combined with a background regimen of nucleoside reverse transcriptase inhibitors, provides potent viral suppression and CD4 cell count recovery.
• Treatment-Experienced Patients: In patients with prior protease inhibitor exposure, darunavir 600mg with ritonavir 100mg twice daily achieves virologic suppression even in the presence of multiple protease inhibitor resistance mutations.
• Paediatric HIV Infection: Approved for children three years and older at weight-appropriate dosages, providing a boosted protease inhibitor option for the paediatric population.
• Multidrug-Resistant HIV: Darunavir is a cornerstone agent for patients with multidrug-resistant HIV who require salvage therapy, demonstrating activity against viral strains resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, and saquinavir.

Why Manufacturers Choose Darunavir

Darunavir is a critical component of modern antiretroviral therapy and is included in WHO treatment guidelines as a preferred protease inhibitor. With India being a major supplier of generic antiretroviral drugs to global HIV treatment programmes including PEPFAR and the Global Fund, darunavir represents a significant market opportunity for WHO-GMP certified manufacturers. The Indian generic version entered the market after patent expirations, and the demand is driven by both domestic and export markets. The tablet formulation requires expertise in hot-melt extrusion technology to enhance bioavailability, which creates a barrier to entry and favours established manufacturers. Given the sustained global commitment to HIV/AIDS treatment and the increasing prevalence of protease inhibitor-containing regimens, darunavir is a strategically important molecule for pharmaceutical companies serving the antiretroviral segment through third-party manufacturing and PCD franchise channels.